These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30227893)

  • 1. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.
    Redman JM; Steinberg SM; Gulley JL
    J Immunother Cancer; 2018 Sep; 6(1):91. PubMed ID: 30227893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
    DeMaria PJ; Lee-Wisdom K; Donahue RN; Madan RA; Karzai F; Schwab A; Palena C; Jochems C; Floudas C; Strauss J; Marté JL; Redman JM; Dombi E; Widemann B; Korchin B; Adams T; Pico-Navarro C; Heery C; Schlom J; Gulley JL; Bilusic M
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM; Gulley JL; Madan RA
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on the clinical development of immunotherapy in prostate cancer.
    Cordes LM; Gulley JL; Madan RA
    Asian J Androl; 2018; 20(3):253-259. PubMed ID: 29582792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.
    Tschernia NP; Gulley JL
    BioDrugs; 2022 Mar; 36(2):153-180. PubMed ID: 35353346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
    Siewe N; Friedman A
    PLoS One; 2022; 17(1):e0262453. PubMed ID: 35015785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in cancer vaccines for immunotherapy of prostate cancer.
    Jin T; Zhou C; Zhao L; Dong X; Zhou F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):148-156. PubMed ID: 36935188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of immunological therapies for prostate cancer.
    Antonarakis ES; Drake CG
    Curr Opin Urol; 2010 May; 20(3):241-6. PubMed ID: 20179598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is There a Role for Immunotherapy in Prostate Cancer?
    Rizzo A; Mollica V; Cimadamore A; Santoni M; Scarpelli M; Giunchi F; Cheng L; Lopez-Beltran A; Fiorentino M; Montironi R; Massari F
    Cells; 2020 Sep; 9(9):. PubMed ID: 32911806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current and emerging role of immunotherapy in prostate cancer.
    Madan RA; Gulley JL
    Clin Genitourin Cancer; 2010 Dec; 8(1):10-6. PubMed ID: 21208850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab in mCRPC - Combination therapies as breakthrough to success?
    Plas S; Pircher A; Heidegger I
    Curr Opin Urol; 2023 Nov; 33(6):458-471. PubMed ID: 37603022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
    Nolan-Stevaux O; Li C; Liang L; Zhan J; Estrada J; Osgood T; Li F; Zhang H; Case R; Murawsky CM; Estes B; Moore GL; Bernett MJ; Muchhal U; Desjarlais JR; Staley BK; Stevens J; Cooke KS; Aeffner F; Thomas O; Stieglmaier J; Lee JL; Coxon A; Bailis JM
    Cancer Discov; 2024 Jan; 14(1):90-103. PubMed ID: 37861452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer.
    Hage Chehade C; Gebrael G; Agarwal N
    Cancer Discov; 2024 Jan; 14(1):20-22. PubMed ID: 38213299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.
    Gulley JL; Drake CG
    Clin Cancer Res; 2011 Jun; 17(12):3884-91. PubMed ID: 21680544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.
    Rausch S; Schwentner C; Stenzl A; Bedke J
    Hum Vaccin Immunother; 2014; 10(11):3146-52. PubMed ID: 25483661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.
    Lasek W; Zapała Ł
    Cent European J Urol; 2021; 74(3):300-307. PubMed ID: 34729217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines as treatments for prostate cancer.
    Rastogi I; Muralidhar A; McNeel DG
    Nat Rev Urol; 2023 Sep; 20(9):544-559. PubMed ID: 36879114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
    Miller KM; Friedman CF
    Clin Cancer Res; 2022 Dec; 28(24):5238-5240. PubMed ID: 35947045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.